Literature DB >> 9269005

Evaluation of visual function following argon laser photocoagulation in central serous retinopathy.

P K Khosla1, S S Rana, H K Tewari, R U Azad, D Talwar.   

Abstract

The authors of previous studies on the role of photocoagulation for central serous chorioretinopathy (CSR) have based their deductions on the premise that a Snellen visual acuity of 6/6 is the end point of recovery. It is now known that patients with a visual acuity of 6/6 may have defective contrast sensitivity indicative of a visual function deficit. The present study was a prospective, controlled, and randomized evaluation of patients suffering from their first attack of CSR, in which contrast sensitivity was used to determine the effectiveness of argon laser photocoagulation as compared with more conservative treatment. Although long-term studies are necessary, the results of this study showed that while photocoagulation increases the rate of recovery for visual acuity, it is also linked with significant loss and slower recovery of contrast sensitivity.

Entities:  

Mesh:

Year:  1997        PMID: 9269005

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers        ISSN: 1082-3069


  26 in total

1.  Effects of photodynamic therapy with verteporfin for the treatment of chronic central serous chorioretinopathy: An uncontrolled, open-label, observational study.

Authors:  Yildirim Bayezit Sakalar; Ugur Keklikci; Kaan Unlu; Mehmet Fuat Alakus; Ismail Hamdi Kara
Journal:  Curr Ther Res Clin Exp       Date:  2010-06

2.  Selective retina therapy in patients with central serous chorioretinopathy.

Authors:  H Elsner; E Pörksen; C Klatt; A Bunse; D Theisen-Kunde; R Brinkmann; R Birngruber; H Laqua; J Roider
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-12       Impact factor: 3.117

3.  Subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy: safety profile and treatment outcome.

Authors:  N K Yadav; C Jayadev; A Mohan; P Vijayan; R Battu; S Dabir; B Shetty; R Shetty
Journal:  Eye (Lond)       Date:  2015-01-23       Impact factor: 3.775

4.  A pilot prospective study of 577-nm yellow subthreshold micropulse laser treatment with two different power settings for acute central serous chorioretinopathy.

Authors:  Lijun Zhou; Victor Chong; Kunbei Lai; Chuangxin Huang; Fabao Xu; Yajun Gong; Maimaitiaili Youlidaxi; Tao Li; Lin Lu; Chenjin Jin
Journal:  Lasers Med Sci       Date:  2019-02-02       Impact factor: 3.161

5.  Selective retina therapy with automatic real-time feedback-controlled dosimetry for chronic central serous chorioretinopathy in Korean patients.

Authors:  Young Gun Park; Seungbum Kang; Minhee Kim; Nari Yoo; Young Jung Roh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-04-18       Impact factor: 3.117

6.  Comparison of subthreshold micropulse laser (577 nm) treatment and half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy.

Authors:  P Scholz; L Altay; S Fauser
Journal:  Eye (Lond)       Date:  2016-07-08       Impact factor: 3.775

7.  Subretinal fibrin absorption after 577-nm subthreshold micropulse laser therapy in a CSC case: a brief report.

Authors:  Lijun Zhou; Tao Li; Kunbei Lai; Chuangxin Huang; Fabao Xu; Zhe Zhu; Lin Lu; Chenjin Jin
Journal:  Lasers Med Sci       Date:  2017-09-05       Impact factor: 3.161

Review 8.  Is ophthalmology evidence based? A clinical audit of the emergency unit of a regional eye hospital.

Authors:  T Y Y Lai; V W Y Wong; G M Leung
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

9.  Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level.

Authors:  W-M Chan; D S C Lam; T Y Y Lai; B S M Tam; D T L Liu; C K M Chan
Journal:  Br J Ophthalmol       Date:  2003-12       Impact factor: 4.638

10.  Indocyanine green enhanced subthreshold diode-laser micropulse photocoagulation treatment of chronic central serous chorioretinopathy.

Authors:  F Ricci; F Missiroli; F Regine; M Grossi; G Dorin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-12-17       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.